PAI Life Sciences Doses First Healthy Volunteer in Schistosomiasis Vaccine Clinical Trial – QNT Press Release

Deadly tropical disease threatens hundreds of millions worldwide

PAI Life Sciences, a biotechnology company specializing in translational research for neglected tropical diseases, today announced the dosing of the first healthy volunteer in a clinical trial of SchistoShield®the company’s preventive vaccine against schistosomiasis, a major tropical disease threatening nearly 1 billion people in 79 countries with more than 260 million people currently infected.

This press release features multimedia. View the full release here:

A study participant received the first-ever shot of the SchistoShield® investigational vaccine at KPWHRI on May 23, 2022. © 2022 Kaiser Permanente Washington Health Research Institute

“Schistosomiasis is one of the deadliest tropical diseases in the world and is second only to malaria among parasitic diseases with the greatest devastating economic impact,” said PAI’s Vice President Sean Gray, Ph.D. “Developing an effective vaccine against schistosomiasis has been elusive , and while many vaccine candidates have been tested, few have offered any significant protection. We at PAI Life Sciences are humbled and excited at the prospect of our vaccine potentially making an impact in disease burden, as there is no effective vaccine to date.”

Schistosomiasis, also known as snail fever, is a disease caused by parasitic flatworms, called schistosomes. The worms enter human skin that comes in contact with contaminated fresh water. They are found in sub-Saharan Africa, …

Full story available on

Source link

Recommended For You

About the Author: News Center